COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,556 Articles (22,881 medRxiv, 8,675 bioRxiv)

Most recent first Previous |  Page 963: Articles 9621-9630  | Next

Preclinical establishment of a divalent vaccine against SARS-CoV-2
Wagner, L., Hevesi, Z., Harkany, T., Gerges, D., Schmetterer, K., Pollak, D., Frey, T., Lang, R., Freire, R., Kapps, S., Schmidt, S., Schmidt, A., Winnicki, W.
10.1101/2022.02.10.479919 — Posted: 2022-02-10
Cell delivery peptides for small interfering RNAs targeting SARS-CoV-2 new variants through a bioinformatics and deep learning design
Gonzalez, R. D., Figueiredo, P. R., Carvalho, A. T. P.
10.1101/2022.02.09.479755 — Posted: 2022-02-10
The rise and fall of SARS-CoV-2 variants and the emergence of competing Omicron lineages
Wiegand, T. R., McVey, A., Nemudraia, A., Nemudryi, A., Wiedenheft, B.
10.1101/2022.02.09.479842 — Posted: 2022-02-10
SARS-CoV-2 Nsp1 N-terminal and linker regions as a platform for host translational shutoff
Graziadei, A., Schildhauer, F., Spahn, C., Kraushar, M. L., Rappsilber, J.
10.1101/2022.02.10.479924 — Posted: 2022-02-10
Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variants
Pitts, J., Li, J., Perry, J., Du Pont, V., Riola, N., Rodriguez, L., Lu, X., Kurhade, C., Xie, X., Camus, G., Manhas, S., Martin, R., Shi, P.-Y., Cihlar, T., Porter, D. P., Mo, H., Maiorova, E. S., Bilello, J. P.
10.1101/2022.02.09.479840 — Posted: 2022-02-10
Dual Inhibition of Cathepsin L and 3CL-Pro by GC-376 Constrains SARS Cov2 Infection Including Omicron Variant
Prabhakar, B. S., Kumar, P., Ratia, K., Richner, J. M., Thatcher, G. R. J., Kadam, R., Smieszek, S. P., Przychodzen, B. P., Koprivica, V., Birznieks, G., Polymeropoulos, M. H.
10.1101/2022.02.09.479835 — Posted: 2022-02-10
Epigenetic Memory of COVID-19 in Innate Immune Cells and Their Progenitors
Cheong, J. G., Ravishankar, A., Sharma, S., Parkhurst, C., Nehar-Belaid, D., Ma, S., Paddock, L., Fatou, B., Karakaslar, E., Thibodeau, A., Bale, M., Kartha, V., Yee, J., Mays, M. Y., Leyre, L., Martinez de Paz, A., Daman, A., Alvarez-Mulett, S., Robbins, L., LaFond, E., Weidman, K., Racine-Brzostek, S., Yang, H., Price, D., Jones, R. B., Schenck, E., Kaner, R., Chadburn, A., Zhao, Z., Steen, H., Pascual, V., Buenrostro, J., Niec, R., Lief, L., Ucar, D., Josefowicz, S.
10.1101/2022.02.09.479588 — Posted: 2022-02-10
Lyophilized mRNA-lipid nanoparticles vaccine with long-term stability and high antigenicity against SARS-CoV-2
Ai, L., Li, Y., Zhou, L., Zhang, H., Yao, W., Han, J., Wu, J., Wang, R., Wang, W., Xu, P., Li, Z., Wei, C., Chen, H., Liang, J., Guo, M., Huang, Z., Wang, X., Zhang, Z., Xiang, W., Lv, B., Peng, P., Zhang, S., Ji, X., Li, Z., Luo, H., Chen, J., Lan, K., Hu, Y.
10.1101/2022.02.10.479867 — Posted: 2022-02-10
Predicting Epitope Candidates for SARS-CoV-2
Agarwal, A., Beck, K. L., Capponi, S., Kunitomi, M., Nayar, G., Seabolt, E., Mahadeshwar, G., Bianco, S., Mukherjee, V., Kaufman, J.
10.1101/2022.02.09.479786 — Posted: 2022-02-10
Engineering Defensin α-helix to produce high-affinity SARS-CoV-2 Spike protein binding ligands.
Fernandes, L. A., Gomes, A. A., Magalhaes, M. d. L. B., Ray, P., da Silva, G. F.
10.1101/2022.02.09.479781 — Posted: 2022-02-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).